Biomarker tests for risk assessment in coronary artery disease: will they change clinical practice?
The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly-even with a multimarker approach-improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.
Department of Internal Medicine III, Cardiology and Angiology, Innsbruck Medical University, Innsbruck, Austria, Johannes.Mair@i-med.ac.at.
Johannes
J
Mair
Allan S
AS
Jaffe
D015415:Biomarkers; D002097:C-Reactive Protein / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D045265:Natriuretic Peptides / Q000378:metabolism*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D014336:Troponin / Q000378:metabolism*
D015415:Biomarkers; D045265:Natriuretic Peptides; D014336:Troponin; D002097:C-Reactive Protein